Compare LOPE & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOPE | AMRX |
|---|---|---|
| Founded | 1949 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 3.8B |
| IPO Year | 2008 | N/A |
| Metric | LOPE | AMRX |
|---|---|---|
| Price | $165.92 | $12.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $220.00 | $13.25 |
| AVG Volume (30 Days) | 436.1K | ★ 2.0M |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.46 | 0.02 |
| Revenue | $1,090,524,000.00 | ★ $2,934,959,000.00 |
| Revenue This Year | $9.20 | $9.99 |
| Revenue Next Year | $6.83 | $6.67 |
| P/E Ratio | ★ $22.24 | $669.75 |
| Revenue Growth | 7.05 | ★ 9.50 |
| 52 Week Low | $149.83 | $6.69 |
| 52 Week High | $223.04 | $12.82 |
| Indicator | LOPE | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.85 | 62.29 |
| Support Level | $158.98 | $12.14 |
| Resistance Level | $158.67 | $12.53 |
| Average True Range (ATR) | 4.43 | 0.33 |
| MACD | 2.84 | -0.01 |
| Stochastic Oscillator | 92.47 | 80.18 |
Grand Canyon Education Inc is a publicly traded education services company dedicated to serving colleges and universities. GCE's university partner is Grand Canyon University, an Arizona non-profit corporation that operates a comprehensive regionally accredited university that offers graduate and undergraduate degree programs, emphases, and certificates across nine colleges both online, on the ground at its campus in Phoenix, Arizona and at four off-site classroom and laboratory sites. The Company generates all of its revenue through services agreements with its university partners.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.